Sermorelin Dosage: Clinical Protocols, Timing & What to Expect

Overview

Sermorelin (sermorelin acetate, also known as GRF 1-29) is a 29-amino acid peptide analog of growth hormone releasing hormone (GHRH). It was the first GHRH analog approved by the FDA (as Geref Diagnostic in 1997) and has the longest clinical track record of any peptide used for GH optimization. Unlike GH secretagogues that act through the ghrelin receptor (ipamorelin, GHRP-6, MK-677), sermorelin works at the GHRH receptor on pituitary somatotroph cells, stimulating GH synthesis and pulsatile release through the same receptor that endogenous GHRH uses. This mechanism preserves the natural feedback loop — the pituitary retains control over GH output, preventing the supraphysiological spikes associated with exogenous GH injection. Sermorelin remains one of the most widely prescribed peptides in US anti-aging and hormone optimization clinics.

Clinical Dosing History and Evidence

Sermorelin's dosing evidence is more extensive than most peptides because of its FDA-approved history and the clinical trials that supported that approval. The original diagnostic use (Geref) employed a single intravenous bolus of 1 mcg/kg to assess pituitary GH reserve. Therapeutic studies explored a wider range. Walker et al. (1990) tested subcutaneous sermorelin at doses of 10, 30, and 100 mcg/kg/day in GH-deficient children, finding dose-dependent increases in growth velocity with 30 mcg/kg/day (approximately 1000-1500 mcg for an average child) producing the most favorable risk-benefit ratio. However, adult dosing for anti-aging and GH optimization has converged on substantially lower doses. In adult clinical practice, 200-300 mcg nightly has become the standard protocol, based on practitioner experience and the pharmacokinetic reality that adults require less exogenous GHRH stimulation to achieve clinically meaningful GH elevation than GH-deficient children. The dose-response curve in adults shows diminishing returns above 300 mcg, with most clinicians reporting that the GH and IGF-1 response at 300 mcg is not meaningfully superior to 200 mcg in the majority of patients. Some aggressive protocols use 500 mcg nightly, particularly in the first 4-6 weeks as a loading phase, before stepping down to 200-300 mcg for maintenance. The evidence supporting loading doses is primarily anecdotal from clinical practice rather than controlled trial data. At the lower end, 100 mcg nightly is sometimes used for maintenance after an initial higher-dose phase or for patients who experience side effects (facial flushing, headache) at standard doses.

• 100 mcg nightly: Low-dose maintenance; suitable for sensitive individuals
• 200 mcg nightly: Standard clinical dose; most common starting point
• 300 mcg nightly: Upper standard dose; commonly prescribed for individuals over 80 kg
• 500 mcg nightly: Loading/aggressive dose; typically limited to first 4-6 weeks

Nightly Injection Timing and Protocol

Sermorelin is always administered at night, typically 30-60 minutes before bed, and this timing is not merely a convenience recommendation — it is pharmacologically critical. The rationale is grounded in the circadian regulation of GH secretion. Approximately 70% of daily GH output occurs during slow-wave sleep (stages 3 and 4), concentrated in the first 1-2 hours after sleep onset. This nocturnal GH surge is initiated by a pulse of endogenous GHRH from the hypothalamus, and sermorelin amplifies this signal by providing additional GHRH receptor stimulation at precisely the time when the pituitary is primed to respond. Daytime injection of sermorelin is substantially less effective because somatostatin tone (the GH-inhibiting hormone) is higher during waking hours, particularly in the postprandial state. The pituitary's responsiveness to GHRH follows a circadian rhythm that peaks in the early sleep period and troughs during mid-day. The fasting requirement is equally important. Food intake, especially carbohydrates, elevates insulin and somatostatin, both of which suppress the pituitary's response to GHRH. The standard clinical recommendation is to inject sermorelin at least 2 hours after the last meal of the day. Some practitioners specify at least 3 hours for optimal results. The injection itself takes only seconds — it is a subcutaneous injection into the abdominal fat or thigh using an insulin syringe (28-31G, 4-8mm needle). Rotation of injection sites is recommended to prevent local tissue irritation, particularly with long-term protocols.

Loading Phase vs Maintenance Phase

Many sermorelin protocols incorporate a two-phase approach: an initial loading phase at higher doses or frequency, followed by a maintenance phase at standard doses. This approach is widely used in clinical peptide therapy but is based on practitioner consensus rather than controlled comparison studies. The loading phase concept is predicated on the observation that the pituitary's response to GHRH stimulation improves with repeated exposure — a phenomenon sometimes called somatotroph priming. In patients with age-related GH decline (somatopause), the pituitary somatotroph cells may have reduced GHRH receptor density and diminished GH synthesis capacity due to chronic understimulation. Repeated nightly GHRH stimulation via sermorelin is thought to upregulate receptor expression and restore somatotroph function over 2-6 weeks. A typical loading protocol uses 300-500 mcg nightly for the first 4-6 weeks, then transitions to 200-300 mcg nightly for maintenance. Some clinicians use a frequency-based loading approach instead: nightly injections for the first 4-6 weeks, transitioning to 5 nights per week (weekdays on, weekends off) for maintenance. The theoretical advantage of periodic breaks is to prevent downregulation of the GHRH receptor, though clinical evidence for this specifically with sermorelin is limited. The maintenance phase is where sermorelin protocols diverge significantly from shorter-acting GH secretagogues. Because sermorelin acts through the physiological GHRH receptor and does not produce supraphysiological GH levels, many clinicians are comfortable prescribing it continuously for months or years as part of an anti-aging regimen. The absence of receptor desensitization (a problem that plagues some GHRPs like hexarelin) supports this approach, though long-term safety data specific to sermorelin in healthy aging adults is limited.

• Loading phase (weeks 1-6): 300-500 mcg nightly; somatotroph priming
• Transition: Reduce to 200-300 mcg nightly at week 4-6
• Maintenance: 200-300 mcg nightly or 5 nights per week
• Some clinics use continuous long-term maintenance for anti-aging
• No evidence of GHRH receptor desensitization with sermorelin

What to Expect: Timeline of Effects

Setting realistic expectations is important because sermorelin works through the body's natural GH regulatory pathway, producing gradual rather than dramatic changes. The timeline below reflects the consensus from clinical practice and patient reports, acknowledging that individual variation is substantial. During the first 1-2 weeks, the most commonly reported benefit is improved sleep quality. Patients describe falling asleep faster, experiencing deeper sleep, and waking feeling more refreshed. This makes physiological sense — the amplified nocturnal GH surge occurs during slow-wave sleep, and GH itself has documented effects on sleep architecture. Some patients report more vivid dreams. By weeks 2-4, improved recovery from exercise and reduced general fatigue become noticeable. This corresponds to IGF-1 reaching a new elevated steady state, as the liver requires 2-3 weeks of sustained GH stimulation to maximally upregulate IGF-1 production. Patients who exercise regularly are typically the first to notice sermorelin's effects because recovery time is a sensitive subjective marker of GH status. Weeks 4-8 bring the beginning of measurable body composition changes. Fat loss — particularly visceral abdominal fat — and improved skin quality (increased collagen synthesis leading to better tone and reduced fine lines) are commonly reported. Lean mass may increase modestly, though gains are subtle and require consistent resistance training to manifest. Months 3-6 represent the period of maximum cumulative benefit. Patients who have been consistent with their protocol report the most significant improvements in body composition, energy, skin, hair quality, and overall sense of vitality during this window. IGF-1 levels are stable, and the body has had sufficient time for the downstream effects of sustained GH optimization to accumulate. This is why 3-6 month protocols are the clinical standard — shorter courses often do not allow sufficient time for the full spectrum of benefits to manifest.

Reconstitution and Practical Administration

Sermorelin is supplied as a lyophilized white powder, typically in vials containing 3 mg, 6 mg, or 9 mg. Compounding pharmacies in the US most commonly dispense 6 mg or 9 mg multi-use vials. Reconstitution follows the same principles as other peptides but the larger vial sizes mean different water volumes and concentration calculations. For a 6 mg vial, adding 3 mL of bacteriostatic water yields a concentration of 2 mg/mL (2000 mcg/mL). At this concentration, a 200 mcg dose requires 0.1 mL (10 units on a U-100 insulin syringe), and a 300 mcg dose requires 0.15 mL (15 units). A 6 mg vial at 200 mcg per night provides approximately 30 doses — sufficient for a full month. For a 9 mg vial, adding 4.5 mL of bacteriostatic water maintains the 2 mg/mL concentration and provides approximately 45 doses. The reconstitution technique is standard: swab the vial stopper with alcohol, draw the measured volume of bacteriostatic water into a syringe, inject slowly down the inside wall of the vial (never directly onto the powder), and gently swirl until dissolved. The solution should be clear and colorless. Store refrigerated at 2-8 degrees Celsius after reconstitution. Sermorelin in solution maintains stability for approximately 21-28 days when properly refrigerated and protected from light. Unreconstituted lyophilized powder should be stored frozen for long-term stability. For subcutaneous injection, use a 28-31G insulin syringe with a 4-8mm needle. Inject into the subcutaneous fat of the lower abdomen (2-3 inches from the navel) or the outer thigh. Rotate injection sites to prevent local tissue changes. The injection is virtually painless when performed correctly.

• 6 mg vial + 3 mL BAW = 2 mg/mL (200 mcg = 10 units; 300 mcg = 15 units)
• 9 mg vial + 4.5 mL BAW = 2 mg/mL (approximately 45 doses at 200 mcg)
• Refrigerate after reconstitution; use within 28 days
• Inject subcutaneously into abdomen or thigh; rotate sites
• Use 28-31G insulin syringe, 4-8mm needle length

Sermorelin vs Alternatives: Dosing Comparison

Understanding how sermorelin's dosing compares to alternative GH-optimizing peptides helps users make informed decisions about which compound — or combination — best suits their needs. Sermorelin acts at the GHRH receptor, producing GH elevation that is firmly physiological. The maximum GH increase from sermorelin alone is limited by the pituitary's intrinsic capacity and the somatostatin feedback loop — this is both a safety feature (preventing supraphysiological GH spikes) and a limitation (the ceiling for GH elevation is lower than with exogenous GH injection). Compared to tesamorelin (another GHRH analog), sermorelin is dosed lower (200-300 mcg vs tesamorelin's FDA-approved dose of 2 mg daily) and produces a more modest GH response. Tesamorelin produces approximately 3-fold higher peak GH levels than sermorelin at their respective standard doses, primarily because tesamorelin is a more potent GHRH receptor agonist with a longer half-life. The clinical trade-off is that sermorelin is more widely available through compounding pharmacies and substantially less expensive. Compared to ipamorelin (a GHRP), sermorelin works through a different receptor entirely. Stacking sermorelin with ipamorelin is pharmacologically rational — the GHRH receptor (sermorelin) and ghrelin receptor (ipamorelin) pathways are synergistic, producing GH output that exceeds either peptide alone. Some clinics prescribe this combination, typically as sermorelin 200-300 mcg plus ipamorelin 200-300 mcg in a single nightly injection. However, the CJC-1295/ipamorelin stack has largely supplanted sermorelin/ipamorelin in clinical practice because CJC-1295 (modified GRF 1-29) is a more potent and stable GHRH analog than sermorelin.

• Sermorelin: 200-300 mcg nightly; moderate GH elevation; physiological
• Tesamorelin: 2 mg daily; stronger GH response; FDA-approved for lipodystrophy
• CJC-1295 no DAC: 100-200 mcg 2-3x daily; more potent GHRH analog
• Ipamorelin: 200-300 mcg 2-3x daily; different receptor (ghrelin); synergistic with sermorelin
• MK-677: 25 mg oral daily; longest-acting; affects appetite more than sermorelin

References

1. Long-term treatment with sermorelin (growth hormone-releasing hormone 1-29) in children with idiopathic growth hormone deficiency (1990) — PubMed
2. Growth hormone-releasing hormone (GHRH) in normal aging: an update (2008) — PubMed
3. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (2005) — PubMed
4. Effects of chronic GHRH administration on GH and IGF-I levels in healthy elderly men and women (2001) — PubMed